|
1) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266
|
|
|
|
2) Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-48
|
|
|
|
|
|
3) Marz W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011; 6: 1316-25
|
|
|
|
|
|
4) Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-407
|
|
|
|
|
|
5) Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011; 22: 1335-41
|
|
|
|
|
|
6) Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-92
|
|
|
|
|
|
7) Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-818
|
|
|
|
|
|
8) Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009; 5: 713-21
|
|
|
|
|
|
9) Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-9
|
|
|
|
|
|
10) Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004; 291: 451-9
|
|
|
|
|
|
11) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22
|
|
|
|
|
|
12) Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58
|
|
|
|
|
|
13) Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004; 110: 1557-63
|
|
|
|
|
|
14) Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009; 54: 810-9
|
|
|
|
|
|
15) Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009; 206: 512-7
|
|
|
|
|
|
16) Shoji T, Masakane I, Watanabe Y, et al. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011; 6: 1112-20
|
|
|
|
|
|
17) Ninomiya T, Kiyohara Y, Kubo M, et al. Meta-bolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006; 48: 383-91
|
|
|
|
|
|
18) Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006; 69: 1264-71
|
|
|
|
|
|
19) Nakamura K, Okamura T, Hayakawa T, et al. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. Circ J. 2006; 70: 954-9
|
|
|
|
|
20) Ninomiya T, Kiyohara Y, Tokuda Y, et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation. 2008; 118: 2694-701
|
|
|
|
|
|
21) Kokubo Y, Nakamura S, Okamura T, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke. 2009; 40: 2674-9
|
|
|
|
|
|
22) Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003; : S207-10
|
|
|
|
|
|
23) Moorhead JF, Chan MK, El-Nahas M, et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982; 2: 1309-11
|
|
|
|
|
|
24) Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14: 2084-91
|
|
|
|
|
|
25) Nakamura T, Kawagoe Y, Ogawa H, et al. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis. 2005; 45: 48-53
|
|
|
|
|
|
26) Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17: 2006-16
|
|
|
|
|
|
27) Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006; 97: 44C-51C
|
|
|
|
|
|
28) Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011; 75: 1493-505
|
|
|
|
|
|
29) Cheng XW, Kuzuya M, Sasaki T, et al. Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens. 2011; 29: 542-52
|
|
|
|
|